Figure 3.

The diagrams illustrate our experimental approaches to validate anti-NMDAR test results by double labeling with a well-characterized mouse anti-NR1 mAb. (A) Single labeling with human blood or CSF samples (standard protocol); (B) sequential double labeling that starts with a human sample (green) and then a mouse anti-NMDAR mAb (orange-red); (C) incorporation of brief fixation (blue bars indicating chemical crosslinkers) after clinical sample labeling. Mouse anti-NR1 mAb thus can no longer compete with human antisera for binding to NMDA receptor, as in (B). Fixed cell membrane and proteins were represented in darker hues.